Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 4, 2009, Pages 281-288

  Kajikawa, Satoshi ^a   Harada, Tsuyoshi ^a   Kawashima, Akiko ^a   Imada, Kazunori ^a   Mizuguchi, Kiyoshi ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; d galactosamine; Eicosapentaenoic acid; Non alcoholic steatohepatitis; Triglyceride

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CONNECTIVE TISSUE GROWTH FACTOR; GALACTOSAMINE; ICOSAPENTAENOIC ACID; OSTEOPONTIN; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARBOHYDRATE DIET; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; HEPATITIS; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CONNECTIVE TISSUE GROWTH FACTOR; DIETARY FATS; DIETARY SUCROSE; EICOSAPENTAENOIC ACID; GALACTOSAMINE; GENE EXPRESSION; HEPATITIS; LIVER; MALE; MICE; MICE, INBRED BALB C; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRIGLYCERIDES;

MUS;

EID: 62249144304     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.01.014     Document Type: Article

References (56)

1. Keppler D., Lesch R., Reutter W., and Decker K. Experimental hepatitis induced by d-galactosamine. Exp. Mol. Pathol. 9 (1968) 279-290
2. Decker K., and Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol., Biochem. Pharmacol. 71 (1974) 77-106
3. Sun F., Hamagawa E., Tsutsui C., Sakaguchi N., Kakuta Y., Tokumaru S., and Kojo S. Evaluation of oxidative stress during apoptosis and necrosis caused by d-galactosamine in rat liver. Biochem. Pharmacol. 65 (2003) 101-107
4. Song H.L., Lu S., and Liu P. Tumor necrosis factor-alpha induces apoptosis of enterocytes in mice with fulminant hepatic failure. World J. Gastroenterol. 11 (2005) 3701-3709
5. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., and Thurman R.G. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 (1999) 942-952
6. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 (2002) 1221-1231
7. Duvnjak M., Lerotic I., Barsic N., Tomasic V., Virovic Jukic L., and Velagic V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J. Gastroenterol. 13 (2007) 4539-4550
8. Lee K.S., Buck M., Houglum K., and Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J. Clin. Invest. 96 (1995) 2461-2468
9. Chu C.J., Lu R.H., Wang S.S., Chang F.Y., Wu S.L., Lu C.L., Chun B.C., Chang C.Y., Wu M.Y., and Lee S.D. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 54 (2007) 2099-2102
10. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., Fang Y., Elariny H., Goodman Z., Chandhoke V., and Younossi Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 27 (2008) 412-421
11. Begriche K., Igoudjil A., Pessayre D., and Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 (2006) 1-28
12. Schreuder T.C., Verwer B.J., van Nieuwkerk C.M., and Mulder C.J. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J. Gastroenterol. 14 (2008) 2474-2486
13. Lombardo Y.B., and Chicco A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem. 17 (2006) 1-13
14. Carpentier Y.A., Portois L., and Malaisse W.J. n-3 fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 83 (2006) 1499S-1504S
15. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., Svegliati-Baroni G., Sofi F., Milani S., Abbate R., Surrenti C., and Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment. Pharmacol. Ther. 23 (2006) 1143-1151
16. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., Papa G., Rabuazzo A.M., and Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 40 (2008) 194-199
17. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., and Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42 (2008) 413-418
18. Yahagi N., Shimano H., Hasty A.H., Amemiya-Kudo M., Okazaki H., Tamura Y., Iizuka Y., Shionoiri F., Ohashi K., Osuga J., Harada K., Gotoda T., Nagai R., Ishibashi S., and Yamada N. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J. Biol. Chem. 274 (1999) 35840-35844
19. Sugiyama E., Ishikawa Y., Li Y., Kagai T., Nobayashi M., Tanaka N., Kamijo Y., Yokoyama S., Hara A., and Aoyama T. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-activated receptor alpha. Life Sci. 83 (2008) 19-28
20. Burton C.A., Patel S., Mundt S., Hassing H., Zhang D., Hermanowski-Vosatka A., Wright S.D., Chao Y.S., Detmers P.A., and Sparrow C.P. Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice. Biochem. Biophys. Res. Commun. 294 (2002) 88-94
21. Dutta R., Singh U., Li T.B., Fornage M., and Teng B.B. Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes. Atherosclerosis 169 (2003) 51-62
22. Wu K.K., Wu T.J., Chin J., Mitnaul L.J., Hernandez M., Cai T.Q., Ren N., Waters M.G., Wright S.D., and Cheng K. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 181 (2005) 251-259
23. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226 (1957) 497-509
24. Hashimoto M., Tanabe Y., Fujii Y., Kikuta T., Shibata H., and Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J. Nutr. 135 (2005) 549-555
25. Sekiya M., Yahagi N., Matsuzaka T., Najima Y., Nakakuki M., Nagai R., Ishibashi S., Osuga J., Yamada N., and Shimano H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38 (2003) 1529-1539
26. Tokushige K., Hashimoto E., Tsuchiya N., Kaneda H., Taniai M., and Shiratori K. Clinical significance of soluble TNF receptor in Japanese patients with non-alcoholic steatohepatitis. Alcohol. Clin. Exp. Res. 29 (2005) 298S-303S
27. Abiru S., Migita K., Maeda Y., Daikoku M., Ito M., Ohata K., Nagaoka S., Matsumoto T., Takii Y., Kusumoto K., Nakamura M., Komori A., Yano K., Yatsuhashi H., Eguchi K., and Ishibashi H. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 26 (2006) 39-45
28. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., and Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4845-4849
29. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., and Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol. 130 (1983) 1910-1917
30. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol.: Gasterointest. Liver Physiol. 279 (2000) G245-249
31. Paradis V., Dargere D., Vidaud M., De Gouville A.C., Huet S., Martinez V., Gauthier J.M., Ba N., Sobesky R., Ratziu V., and Bedossa P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30 (1999) 968-976
32. Sahai A., Malladi P., Pan X., Paul R., Melin-Aldana H., Green R.M., and Whitington P.F. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol.: Gasterointest. Liver Physiol. 287 (2004) G1035-1043
33. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112 (2003) 91-100
34. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
35. Shinozuka H., Farber J.L., Konishi Y., and Anukarahanonta T. d-galactosamine and acute liver cell injury. Fed. Proc. 32 (1973) 1516-1526
36. Bruguera M., Bertran A., Bombi J.A., and Rodes J. Giant mitochondria in hepatocytes: a diagnostic hint for alcoholic liver disease. Gastroenterology 73 (1977) 1383-1387
37. Robertson N.J., and Kendall C.H. Liver giant mitochondria revisited. J. Clin. Pathol. 45 (1992) 412-415
38. Yang S., Lin H., and Diehl A.M. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am. J. Physiol.: Gasterointest. Liver Physiol. 281 (2001) G382-392
39. Serafin A., Rosello-Catafau J., Prats N., Xaus C., Gelpi E., and Peralta C. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am. J. Pathol. 161 (2002) 587-601
40. Le T.H., Caldwell S.H., Redick J.A., Sheppard B.L., Davis C.A., Arseneau K.O., Iezzoni J.C., Hespenheide E.E., Al-Osaimi A., and Peterson T.C. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 39 (2004) 1423-1429
41. Caldwell S.H., Swerdlow R.H., Khan E.M., Iezzoni J.C., Hespenheide E.E., Parks J.K., and Parker Jr. W.D. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31 (1999) 430-434
42. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., Fernandez-Escalante J.C., and Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
43. Miyazaki Y., Pipek R., Mandarino L.J., and DeFronzo R.A. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 88-94
44. Diehl A.M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin. Liver Dis. 8 (2004) 619-638
45. Sanchez-Alcazar J.A., Schneider E., Hernandez-Munoz I., Ruiz-Cabello J., Siles-Rivas E., de la Torre P., Bornstein B., Brea G., Arenas J., Garesse R., Solis-Herruzo J.A., Knox A.J., and Navas P. Reactive oxygen species mediate the down-regulation of mitochondrial transcripts and proteins by tumour necrosis factor-alpha in L929 cells. Biochem. J. 370 (2003) 609-619
46. Galli A., Svegliati-Baroni G., Ceni E., Milani S., Ridolfi F., Salzano R., Tarocchi M., Grappone C., Pellegrini G., Benedetti A., Surrenti C., and Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41 (2005) 1074-1084
47. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
48. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
49. Madsen L., and Berge R.K. 3-Thia fatty acid treatment, in contrast to eicosapentaenoic acid and starvation, induces gene expression of carnitine palmitoyltransferase-II in rat liver. Lipids 34 (1999) 447-456
50. Sohma R., Takahashi M., Takada H., Takada H., and Kuwayama H. Protective effect of n-3 polyunsaturated fatty acid on primary culture of rat hepatocytes. J. Gastroenterol. Hepatol. 22 (2007) 1965-1970
51. Ikeda I., Cha J.Y., Yanagita T., Nakatani N., Oogami K., Imaizumi K., and Yazawa K. Effects of dietary alpha-linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and beta-oxidation in rats. Biosci. Biotechnol. Biochem. 62 (1998) 675-680
52. Armstrong M.B., and Towle H.C. Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalpha-mediated pathway. Am. J. Physiol: Endocrinol. Metab. 281 (2001) E1197-1204
53. Demoz A., Willumsen N., and Berge R.K. Eicosapentaenoic acid at hypotriglyceridemic dose enhances the hepatic antioxidant defense in mice. Lipids 27 (1992) 968-971
54. Itoh M., Suganami T., Satoh N., Tanimoto-Koyama K., Yuan X., Tanaka M., Kawano H., Yano T., Aoe S., Takeya M., Shimatsu A., Kuzuya H., Kamei Y., and Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1918-1925
55. Sierra S., Lara-Villoslada F., Comalada M., Olivares M., and Xaus J. Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects. Nutrition 24 (2008) 245-254
56. Zhao Y., Joshi-Barve S., Barve S., and Chen L.H. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J. Am. Coll. Nutr. 23 (2004) 71-78